drugset / Trial / NCT04724369
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Phase 3
Active not recruiting
43 enrolled
Innervate Radiopharmaceuticals LLC
Memorial Sloan Kettering Cancer Center · collabNew Approaches to Neuroblastoma Therapy Consortium · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
Timeline
- Start
- 2021-11-18
- Primary completion
- 2026-07-30
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M-FLUOROBENZYLGUANIDINE | Diagnostic / imaging agent | — | — |